Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas
Article 2024 en
Authors
AG
Alice B. Gottlieb
AA
April W. Armstrong
AB
Andrew Blauvelt
Abstract
1 min read
For most efficacy measures, patients treated with ixekizumab over 5 years achieved similar clear responses and cumulative clinical benefits regardless of baseline involvement of challenging body areas. J Drugs Dermatol. 2024;23(8):619-625. doi:10.36849/JDD.8160.
Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, Christopher Em Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, S.Y. Park, Baojin Zhu, Kim Papp
Christopher Em Griffiths, Matthias Hoffmann, Andrew Blauvelt, Eugene Balagula, Andrew Napoli, Chun-Yen Cheng, Rachel Dyme, Virginia Hala, Andreas Pinter, Mark Lebwohl
Ashutosh Wechalekar, Efstathios Kastritis, Giampaolo Merlini, Philip N. Hawkins, Meletios A Dimopoulos, Julian D. Gillmore, Simon Gibbs, Giovanni Palladini
Meletios A Dimopoulos, Philippe Moreau, Bradley Augustson, Nelson Castro, Tomáš Pika, Sosana Delimpasi, Javier de la Rubia, Ângelo Maiolino, Tony Reiman, Joaquín Martínez‐López, Thomas G. Martin, Joseph Mıkhael, Kwee Yong, Marie‐Laure Risse, Gaëlle Asset, Sylvia Marion, Roman Hájek
Christian A. Di Buduo, Pierre Laurent, Carlo Zaninetti, Larissa Lordier, Paolo M. Soprano, Aikaterini Ntai, Serena Barozzi, Alberto Spada, Ida Biunno, Hana Raslová, James B. Bussel, David Kaplan, Carlo L. Balduini, Alessandro Pecci, Alessandra Balduini
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.